Search press releases
Search entire Web site Go
UMHS Home/Logo
 

March 6, 2006

U-M study: Cost-effectiveness of growth hormone therapy for kids may not measure up

Using growth hormone therapy, kids with Idiopathic Short Stature only grew about 2 inches at average cost of $100,000; could cost $40 billion to treat all kids with ISS

ANN ARBOR, MI – How much would you pay to be about 2 inches taller?

For children with Idiopathic Short Stature (ISS) – a condition of unknown origin that causes kids to grow well below the normal height range – it would cost as much as $100,000 for one child to grow an average of 2 additional inches using growth hormone therapy for five years.

This finding comes from researchers at the University of Michigan C.S. Mott Children’s Hospital who analyzed the cost-effectiveness of growth hormone for children with ISS. They are the first to conduct such a study using clinical trial data that were the basis for the U.S. Food and Drug Administration’s July 2003 approval of recombinant growth hormone for the long-term treatment of children with ISS.

The study, appearing in the March issue of the Archives of Pediatric and Adolescent Medicine, revealed that the incremental cost-effectiveness of growth hormone therapy for ISS was more than $52,000 per inch.

In all, it would cost about $40 billion dollars to treat the estimated 400,000 American children ages 4 to 15 who are now eligible for growth hormone therapy under the ISS indication, says study lead author Joyce Lee, M.D., with the Division of Pediatric Endocrinology and Child Health Evaluation Research (CHEAR) Unit in the Division of General Pediatrics at U-M.

“Due to variability in the growth response we found in children with ISS, targeted treatment of children with ISS who have the greatest potential for growth is critical to improve the cost-effectiveness of this therapy,” says Lee.

Children with ISS represent the shortest 1.2 percent of all children based on age and gender. Since they are otherwise healthy children, there is considerable debate about the costs and benefits for a 1- to 2-inch height gain from hormone therapy.

With such a large group of children now eligible for growth hormone therapy, Lee says it was critical to reassess its cost-effectiveness based on the efficacy data used for the FDA approval, and also to evaluate the cost-effectiveness of alternative growth hormone treatment strategies for ISS.

To determine the cost-effectiveness of the therapy, Lee and her colleagues compared the height gain by adulthood for children treated for five years with growth hormone therapy to that of children who received no medical intervention.

The study focused on children with ISS who had no evidence of growth hormone deficiency or other known medical conditions that might compromise their growth.

Results revealed that the incremental cost-effectiveness of growth hormone therapy for ISS was approximately $100,000 per child, or $52,000 per inch – substantially higher than a previous cost estimate of $35,000 per inch.

Cost of the medication was a major factor in the cost-effectiveness estimates, notes Lee. For example, if the typical cost for the growth hormone was cut in half, the cost-effectiveness would be markedly lower, at $25,000 per inch.

“With the rising cost of prescription drug therapies in the country, growth hormone therapy for ISS has the potential to become one of the major challenges facing our health care system today,” says Lee.

To improve the cost-effectiveness of growth hormone therapy, Lee says more research needs to be done to help physicians identify children likely to have the greatest potential for growth.

Additionally, she stresses the need to have future research examine the psychological outcomes related to growth hormone therapy use.

Lee’s study solely focused on cost-effectiveness based on the outcome of height gain by adulthood. It did not evaluate the impact of growth hormone therapy on improvements to quality of life, or the possible long-term effects on salary and future earnings. Both are critical indicators for growth hormone therapy use, Lee says, and currently there is no research that demonstrates that it improves the quality of life for children with ISS.

Along with Lee, co-authors from the CHEAR Unit in the Division of General Pediatrics were Matthew M. Davis, M.D., MAPP; Sarah J. Clark, MPH; and Alex R. Kemper, M.D., MPH, MS; and Timothy P. Hofer, M.D., Veterans Affairs Health Services Research and Development at  the VA Ann Arbor Healthcare System.

The study was supported by a Pediatric Health Services Research Training Grant from the National Institutes of Child Health and Human Development.     

Reference: Archives of Pediatric and Adolescent Medicine, March 2006, Vol. 160, No. 3.

Written by Krista Hopson 

 

E-mail this information to a friend

Recent Press Releases

 


Newsroom HOME

Contact Media Team

Join the Media List

Search Releases & Clips

UMHS Facts & Figures

Background Info

Video/Audio/Images

Our Publications

FAQs for Media





Medical School | Hospitals and Health Centers | School of Nursing | U-M

University of Michigan Health System
1500 E. Medical Center Drive  Ann Arbor, MI 48109  734-936-4000
(c) copyright Regents of the University of Michigan
Developed & maintained by: Public Relations & Marketing Communications
Contact UMHS

 


The University of Michigan Health System web site does not provide specific medical advice and does not endorse any medical or professional service obtained through information provided on this site or any links to this site.
Complete Disclaimer and Privacy Statement

UMHS HOME

Health Topics A-Z

For Patients & Families

For Health Professionals

Search Tools & Index